The strain dependency of the spectrum and latency of tumors has been reported in p53-deficient (KO) mice, suggesting the presence of modifiers for the outcome of the p53 deficiency. The modifiers provide clues to the oncogenic pathway in cells lacking p53, the most frequently mutated gene in a wide variety of human cancers. To search the modifiers, we induced 160 lymphomas and 69 skin tumors by c-irradiation of p53(KO/+) backcross mice between BALB/c and MSM strains and performed genome scan. BALB/cderived alleles at three loci on chromosome 19, Mp53D1 (modifier of p53-deficiency) at D19Mit5, Mp53D2 at D19Mit90 and Mp53D3 at D19Mit123, extended the latency of thymic lymphoma development (P values in Mantel-Cox test were 0.0007, 0.0007 and 0.0003, respectively). Mp53D3 also increased the latency of skin tumors (P value, 0.0008). The linkage of Mp53D2 was confirmed by the experiment using 94 p53-KO mice consomic for chromosome 19, providing a significant linkage. However, the linkage was not confirmed for Mp53D1 or Mp53D3, suggesting epistasis of genes involved in the tumorigenesis.
Individuals inheriting the same mutation predisposing to cancer often express different phenotypes with respect to the spectrum and latency of tumors. Li-Fraumeni patients with p53 gene mutations, for instance, are susceptible to sarcomas and the breast carcinoma, and their outcomes range from early aggressive cancer to disease-free survival (Malkin et al., 1990; Greenblatt et al., 1994) . This may reflect the presence of lowpenetrance genes in the human population as well as environmental factors that can modify the impact of a given mutation (Demant, 1992; Balmain and Nagase, 1998; Ponder, 2001 ). The identification of modifier genes is important both for their possible public health implications and for the fundamental understanding of the cancer development. Experimental mouse models may provide a powerful tool to search genes of this type (Balmain and Nagase, 1998; Nadeau, 2001; Balmain, 2002) . p53-deficient (p53-KO) mice develop tumors at a very young age and heterozygotes are extremely susceptible to radiation-induced thymic lymphomas (Donehower et al., 1992; Kemp et al., 1994) . Straindependent differences in tumorigenesis are evident and the p53-KO mice of 129/Sv background develop tumors sooner than do their counterparts of C57BL/6 background (Donehower et al., 1995) . Moreover, the predominant tumor type is lymphoma in the p53-KO C57BL/6 mice, whereas testicular teratomas are as common as lymphomas in the null 129/Sv strain. These results suggest the existence of modifiers for the impact of p53 deficiency. However, further investigation of the strain dependence has not been performed.
We induced tumors by g-irradiation of p53(KO/+) F1 hybrid and N2 backcross mice between BALB/c and MSM strains (Table 1) . Almost all mice developed tumors, most of which were thymic lymphomas. Interestingly, p53(KO/+) N2M (backcrossed to MSM) mice developed skin tumors at a frequency of 27% (69/ 251), whereas p53(KO/+) F1 and p53(KO/+) N2C (backcrossed to BALB/c) mice developed them at much lower frequencies (6 and 5%, respectively). Figure 1a shows the cumulative frequency distribution of thymic lymphomas and skin tumors in p53(KO/+) N2M mice, indicating their distinct latencies. Besides, only six mice developed both thymic lymphoma and skin tumors (Table 1) . These allowed us to perform association study separately.
Association was examined between the latency of thymic lymphoma development and genotypes using 67 microsatellite marker loci (Dietrich et al., 1996) . The average and maximum distances between the marker loci were 24 and 36 cM, respectively. As a primary screen, we chose a group of 20 mice among the 160 p53(KO/+) N2M that developed lymphomas at a later Distributions of skin tumors in heterozygotes and homozygotes of N2M backcross mice at D19Mit123. Genotyping of p53 and microsatellite markers was carried out as described previously (Saito et al., 2001; Matsumoto et al., 1998) . w 2 and P values for association of markers with the development of thymic lymphomas or skin tumors were obtained by the Mantel-Cox test with StatView-J 5.0 software on a Macintosh personal computer. Evaluation of linkage followed the criteria of Lander and Kruglyak (1995) . Linkage was taken as suggestive in the backcross mice when P was less than 0.0034 and was significant when P was less than 0.0001 Table 1 Number of p53(KO/+) mice bearing tumors after g-ray irradiation The cell type of skin tumors is benign demarcated tumor of skin appendage origin (Miyazawa et al., 2002) d
The tumors included leukemia, splenic tumors, ovarian cancers, and were omitted in the association study. p53-deficient mice of MSM background were produced as described previously (Matsumoto et al., 1998) and those of BALB/c background were by Mori et al (1999) . Consomic mice for chromosome 19 were obtained by backcrossing six times according to the marker-assisted protocol (Markel et al., 1997) ; a total of 111 polymorphic markers were employed that were distributed throughout the genome. Progeny of the mice were subjected to fractionated doses of g-ray irradiation, 2.5 Gy four times at a week interval, when they were at the age of 4 weeks. Development of thymic lymphomas was diagnosed by the inspection of labored breathing up to 300 and 250 days for N2 M backcross mice and consomic mice, respectively, and that of skin tumors by inspection and palpation of tumor mass under skin. Existence of tumors was confirmed upon autopsy of the mice
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Hence, genotyping was performed on the rest of 140 N2M mice for 11 loci on chromosome 19. Figure 2 displays the distribution of w 2 values calculated using the MapManager/QTX software (Manly et al., 2001) for the latencies, indicating three peaks of the association at D19Mit5, D19Mit90 and D19Mit123. This suggested three different p53 modifiers of BALB/c origin that contributed for extension of the latency. We tentatively named them Mp53D1, Mp53D2 and Mp53D3, respectively (modifiers of the p53-deficient allele). Figure 1b-d show Kaplan-Meier plots for C/M heterozygotes and M/M homozygotes at the three loci. P values in Mantel-Cox test were 0.0007 at D19Mit5, 0.0007 at D19Mit90, and 0.0003 at D19Mit123, which were all indicated to be between suggestive and significant linkages by the criteria of Lander and Kruglyak (1995) .
Effect on the latency of skin tumors was similarly examined by the genome-wide scan. Results revealed that mice with the C/M genotype at the D19Mit123 locus showed the latency longer than that of the M/M mice ( Figure 1e ). The locus was the same as Mp53D3 for the lymphoma development, although it was uncertain whether the same gene(s) was responsible for the two different effects (Figure 2 ). On the other hand, since only a group of p53(KO/+) N2M mice developed skin tumors at a high frequency (Table 1) , it is likely that a combination of the p53-deficient allele and the MSM allele in some locus raised the incidence of skin tumors. However, our genome-wide association analysis failed to find any locus that provided the preference to skin tumor development (data not shown). At the D19Mit123 locus, skin tumor-bearing mice of the C/M and the M/M genotypes were 42 and 27, respectively, whereas lymphoma-bearing mice of the same genotypes were 89 and 71, respectively (P ¼ 0.41).
To provide additional evidence for the p53 modifier, we generated consomic mice for chromosome 19 by backcrossing MSM to BALB/c six times according to the marker-assisted protocol (Markel et al., 1997) . The consomic mice were mated with p53(KO/+) BALB/c mice. The mice heterozygous for chromosome 19 and carrying a p53-deficient allele were chosen and crossed with MSM mice. A total of 189 offsprings, a half of which were of F1 background and the others of F1 background except for the consomic region, were subjected to g-irradiation. In all, 94 mice were p53(KO/+) by p53 genotyping and 85 of them developed thymic lymphomas and three developed skin tumors (Table 1) . Genotyping with the 11 markers on chromosome 19 revealed that 21 and 24 mice received a whole BALB/c or MSM chromosome, respectively, from the heterozygous mice and 40 inherited recombinant chromosomes. w 2 test provided the strongest association of lymphomas at D19Mit90 but not at D19Mit5 or D19Mit123 (Figure 2 ). Figure 3a shows the cumulative incidences of lymphomas among homozygotes and heterozygotes at the D19Mit90 locus, and Figure 3b displays those of p53(KO/À) lymphomas. Their P values were 0.0026 and 0.0020, respectively.
Since a value less than 0.0035 is the threshold to achieve a false positive rate smaller than 5% (see the legend to Figure 3 ), these results confirmed the presence of the p53 modifier of Mp53D2 but not of Mp53D1 or Mp53D3.
Certain susceptibility loci were found to be mutated tumor suppressor genes (Balmain and Nagase, 1998; Ponder, 2001) . It is possible that a BALB allele of Mp53D2 could be a functional tumor-suppressor gene while the MSM allele was a mutated one, since the BALB/c allele conferred resistance for the lymphoma development. Hence, allelic loss was examined for 387 lymphomas that we had induced in our laboratory. The frequency of allelic loss was 15.8% (59/387), centered at the D19Mit132(21.9 cM)-D19Mit5(24 cM) region. This may suggest the existence of a tumor-suppressor gene in the vicinity. Even though this may be the case, the gene and Mp53D2 are likely to differ because no allelic preference was observed, BALB/c loss being 30 and MSM loss 29.
Exposure of p53(KO/+) mice to ionizing radiation dramatically decreases their life span owing to the development of thymic lymphomas in most cases (Kemp et al., 1994) . The present genetic study uncovered a locus, Mp53D2, modifying the lifespan near D19Mit90 on mouse chromosome 19. The linkage was suggested by an analysis using backcross mice and was confirmed by the use of the consomic mice. There were two other modifier loci, Mp53D1 and Mp53D3, suggested by the genome scan for the latencies of thymic lymphomas, and Mp53D3 was also shown to modify the latencies of skin tumors. However, these two loci were not confirmed by analysis of the consomic mice. This may indicate false linkages. Alternatively, the genome scan of backcross mice may have detected epistasis of genes involved in lymphomagenesis or the skin tumor development, such as interactions between the p53-KO allele and the MSM-derived or BALB/c-derived alleles. These interactions may also explain the low statistical values obtained from the genome scan. On the other hand, alleles present in the MSM genetic background probably increased the susceptibility of p53(KO/+) mice to skin tumors and instead decreased the incidence of lymphomas, since skin tumor was observed in only small fractions of F1 and N2C p53(KO/+) mice (Table 1) . This suggests that the MSM background carries a modifying allele(s) that has an impact on the spectrum of tumors. However, we failed to find such a locus, suggesting that multiple modifiers rather than a single modifier contribute to the tumor spectrum. This is consistent with the fact that only three among the 94 consomic p53(KO/+) mice developed skin tumors (Table 1) . The nature of the gene product encoded by Mp53D2 remains to be identified. Although the modifier locus may involve a factor extrinsic to the tumor cell lineage, as exemplified by Mom1 (Su et al., 1992; Macphee et al., 1995; Cormier et al., 1997) , it is more probable that the locus acts intrinsically because of genetic interaction with p53 loss in the development of thymic lymphomas. As for p53 wild-type mice, the locus did not affect the incidence and latency of lymphoma after exposure to ionizing radiation (Saito et al., 2001) , since the P value in the Mantel-Cox test was 0.12 (w 2 ¼ 2.4). In contrast to Mp53D2, the D4Mit12 locus that we previously mapped as a lymphoma susceptibility locus using p53 wild-type mice (Saito et al., 2001) little extended the lymphoma latency in the p53(KO/+) mice (w 2 ¼ 2.6, P ¼ 0.11). The action intrinsic might affect the penetrance of p53(KO/ +) genotype by conferring a resistance (or a susceptibility) for the inactivation of the p53 wild-type allele via recombination or point mutations in lymphomas. Dmp1 probably on mouse chromosome 5 is one such example (Inoue et al., 2001) . This is less likely for Mp53D2, however, because the frequency of the p53 wild-type allele loss or K-ras mutations did not differ between homozygotes and heterozygotes at D19Mit90 or in the vicinities (data not shown).
Polymorphic forms of the Mp53D2 product might determine the ability to respond to p53 loss or might permit redundancy by utilization of an alternative pathway other than the p53 signaling pathway as reported by others (Greenblatt et al., 1994; Giaccia and Kastan, 1998; Sionv and Haupt, 1999) . The p73 or p63/p51 pathway could be directly or indirectly involved in the action of the polymorphic locus, although their chromosomal loci are not on chromosome 19 (Kaghad et al., 1997; Osada et al., 1998; Yang et al., 1998 Yang et al., , 2002 . Pten is located in the vicinity of Mp53D2 and one of the downstream genes on the p53 signaling pathway (Stambolic et al., 2001) . Pten heterozygous mice develop neoplasia in multiple tissues that includes lymphoid hyperplasias but not malignancies of T cells or the thymus (Podsypanina et al. 1999) . Therefore, Pten is less likely to be Mp53D2. Other candidates within this chromosomal region were not found by database search. Hence, further efforts should be made toward positional cloning of Mp53D2 by generating congenic strains to narrow down the candidate region for lymphoma susceptibility. (Matsumoto et al., 1998) . Evaluation of linkage followed the criteria of Lander and Kruglyak (1995) . The statistical threshold of the consomic mouse data was corrected for multiple comparisons using the formula m(T) ¼ [ 05. To achieve a false positive rate of 5% or less in the analysis of markers on the congenic region, we used a P ¼ 0.0034 threshold
